{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:50:26Z","timestamp":1773773426046,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1749,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1111\/j.1478-3231.2010.02368.x","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T03:38:22Z","timestamp":1290051502000},"page":"369-376","source":"Crossref","is-referenced-by-count":53,"title":["Early \u03b1-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma"],"prefix":"10.1111","volume":"31","author":[{"given":"Beom Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Sil","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,17]]},"reference":[{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P","article-title":"Estimates of the worldwide incidence of 25 major cancers in 1990","volume":"80","author":"Parkin","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Sherman","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB4|cit4","first-page":"25","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma","volume":"10","author":"Cheng","year":"2009","journal-title":"a phase III randomised, double-blind, placebo-controlled trial"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB6|cit6","first-page":"67","article-title":"Commentary","volume":"14","author":"Zhu","year":"2009","journal-title":"sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB7|cit7","first-page":"1653","article-title":"Radiation therapy for hepatocellular carcinoma","volume":"106","author":"Hawkins","year":"2006","journal-title":"from palliation to cure"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23684","article-title":"Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis","volume":"113","author":"Han","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1200\/JCO.2005.01.5354","article-title":"Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies","volume":"23","author":"Ben-Josef","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.ijrobp.2009.07.1676","article-title":"Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas?","volume":"77","author":"Koom","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada","volume":"92","author":"Gwyther","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB13|cit13","first-page":"61","article-title":"Current strategy for staging and treatment","volume":"30","author":"Forner","year":"2010","journal-title":"the BCLC update and future prospects"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00000658-200102000-00013","article-title":"Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma","volume":"233","author":"Lau","year":"2001","journal-title":"Ann Surg"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB15|cit15","first-page":"5734","article-title":"Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma","volume":"27","author":"Riaz","year":"2009","journal-title":"oncologic marker of radiologic response, progression, and survival"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB16|cit16","first-page":"446","article-title":"New utility of an old marker","volume":"27","author":"Chan","year":"2009","journal-title":"serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB17|cit17","first-page":"1329","article-title":"Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma","volume":"64","author":"Johnson","year":"1980","journal-title":"influence of therapy and possible value in early detection"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3350\/kjhep.2009.15.3.391","article-title":"Practice guidelines for management of hepatocellular carcinoma 2009","volume":"15","author":"Korean Liver Cancer Study Group and National Cancer Center.","year":"2009","journal-title":"Korean J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/1097-0142(197602)37:2<677::AID-CNCR2820370211>3.0.CO;2-T","article-title":"Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma","volume":"37","author":"Mcintire","year":"1976","journal-title":"Cancer"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB20|cit20","first-page":"395","article-title":"Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma","volume":"24","author":"Ueno","year":"2002","journal-title":"a validation analysis"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2005.12.015","article-title":"Prospective validation of the Barcelona clinic liver cancer staging system","volume":"44","author":"Cillo","year":"2006","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1386-6346(03)00162-1","article-title":"Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients","volume":"27","author":"Seong","year":"2003","journal-title":"Hepatol Res"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2009-0038","article-title":"Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma","volume":"14","author":"Vora","year":"2009","journal-title":"Oncologist"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB24|cit24","first-page":"459","article-title":"Hepatocellular carcinoma","volume":"51","author":"Johnson","year":"2002","journal-title":"is current therapy really altering outcome?"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1586\/14737140.3.4.421","article-title":"Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma","volume":"3","author":"Johnson","year":"2003","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB26|cit26","first-page":"12","article-title":"Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy\/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma","volume":"5","author":"Zhao","year":"2010","journal-title":"a phase I\/II study"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2009.07.1725","article-title":"Angiogenic blockade and radiotherapy in hepatocellular carcinoma","volume":"78","author":"Chi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1038\/sj.onc.1209706","article-title":"Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K\/Akt\/NF-kappaB signal transduction pathway","volume":"25","author":"Cheng","year":"2006","journal-title":"Oncogene"},{"key":"10.1111\/j.1478-3231.2010.02368.x-BIB29|cit29","first-page":"2706","article-title":"Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells","volume":"12","author":"Chung","year":"2006","journal-title":"implications for radiotherapy of hepatocellular carcinoma"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02368.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1478-3231.2010.02368.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T04:46:23Z","timestamp":1612673183000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/j.1478-3231.2010.02368.x"}},"subtitle":["AFP response in hepatocellular carcinoma"],"short-title":[],"issued":{"date-parts":[[2010,11,17]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02368.x","relation":{},"ISSN":["1478-3223"],"issn-type":[{"value":"1478-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,17]]}}}